Kairos Capital Management is a fund manager in Rye with $453.53 mm assets under management.
Company profile
Website
Employees
Incorporated
Fiscal year end
Industry
SEC CIK
IRS number
843799363
SEC advisor number
801-119993
FINRA CRD number
310191
AUM ?
$453.53 mm
(as of 29 Apr 22)
Accounts
8
(as of 29 Apr 22)
Employees
8
(5 investment advisory or research)
Office hours
Monday - Friday, 9-5
Ownership
Owner | Title | From | %Ownership |
---|---|---|---|
Toussi, Sina | Limited Partner / Chief Investment Officer | 12/2019 | 50-75% |
Two Seas Capital GP LLC | General Partner | 10/2019 | < 5% |
Toussi, Sina | Member | 10/2019 | > 75% |
Palermo, Lawrence, Vincent | Chief Compliance Officer / Chief Financial Officer | 11/2020 | 5-10% |
Bennett, John, Patrick | Managing Director / Head Trader | 03/2021 | 5-10% |
Sheth, Himanshu, Dipak | Managing Director / Head of Research | 03/2021 | 10-25% |
Chasen, David, Scott | Managing Director | 03/2021 | 5-10% |
Ownership
Fund structure | AUM | Fund type |
---|---|---|
Two Seas Capital LP | $453.53 mm | |
Two Seas Duration Litigation Opportunities Fund LLC - Class 1 | $4.12 mm | Hedge Fund |
Two Seas Duration Litigation Opportunities Fund LLC - Class 2 | $29.99 mm | Hedge Fund |
Two Seas Duration Litigation Opportunities Fund LLC - Class 3 | $33.48 mm | Hedge Fund |
Two Seas Duration Litigation Opportunities Fund LLC - Class 4 | $1.28 mm | Hedge Fund |
Two Seas Global (Master) Fund LP | $192.83 mm | Hedge Fund |
Two Seas Global (Domestic) Fund LP | $55.19 mm | Hedge Fund |
Two Seas Global (Cayman) Fund LP | $27.65 mm | Hedge Fund |
Two Seas Litigation Opportunities Fund LLC | $190.80 mm | Hedge Fund |
Latest filings (excl ownership)
No filings
Latest ownership filings
SC 13G/A
Esperion Therapeutics, Inc.
14 Feb 24
SC 13G/A
Arbutus Biopharma Corp
14 Feb 24
SC 13G/A
ODYSSEY MARINE EXPLORATION INC
14 Feb 24
13F-HR
Quarterly holdings report by institutional manager
14 Feb 24
SC 13G
Arbutus Biopharma Corp
21 Nov 23
13F-HR
Quarterly holdings report by institutional manager
14 Nov 23
SC 13G
Esperion Therapeutics, Inc.
5 Oct 23
SC 13D
INDIVIOR PLC
2 Oct 23
13F-HR
Quarterly holdings report by institutional manager
14 Aug 23
13F-HR
Quarterly holdings report by institutional manager
15 May 23